🔍 Concall Decoded

🎙 Management Tone Tracker Mixed → Stable 4 quarters analysed

Q1 2026

Mixed

projecting strong earnings growth and margin expansion.

Q2 2026

Mixed

stating 'we delivered margin expansion, a substantial increase in earnings' and 'we are reaffirming our outlook'. They detailed growth drivers (32% Kyndryl Consult, hyperscaler doubling) and explicitly quantified second-half growth levers.

Q3 2026

Mixed

longer sales cycles, and an evolving IBM partnership. Martin Schroeter acknowledges 'we fell short' and 'the world is getting more complex' while emphasizing confidence in FY2028 targets. The prepared remarks and Q&A avoid detailed forward commentary on the SEC review, and management stresses operational adjustments.

Q4 2026 latest

Mixed

margin expansion, over $400 million free cash flow') but candidly identified headwinds ('extended sales cycles, weigh on revenue and signings'). They provided specific guidance ranges ($600-700M adjusted pre-tax income, flat to down 2% revenue) and detailed progress on initiatives (Kyndryl Consult double-digit growth, $1.9B hyperscaler revenue).

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis remains broadly intact but with a tempered revenue outlook due to IBM relationship headwinds and persistent longer sales cycles. Management provided specific profit and cash flow targets for FY2028, relying on higher-margin signings and cost actions rather than top-line acceleration. The key change from prior expectations is that revenue growth may be lower than originally modeled, but profit growth is still achievable if low single-digit revenue growth occurs. The first quarter of FY2027 will be critical to watch for earnings trough and signs of sales cycle improvement, especially in Europe where sovereignty discussions are delaying decisions. The stock's narrative now depends on execution of workforce rebalancing and conversion of consult pipeline into revenue. Without evidence of sales cycle normalization, revenue growth may remain constrained, but margin expansion and cash flow generation provide downside protection.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Mixed → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Kyndryl reports $15.1B revenue, $406M free cash flow in FY2026.

Revenue & Profitability

Fiscal 2026 revenue was $15.1 billion, flat reported, down 3% constant currency. Adjusted EBITDA was $2.7 billion, adjusted pre-tax income $581 million, and free cash flow $406 million. Total signings were $13.5 billion. The company reported a gross profit book-to-bill ratio above 1x over the last three years, indicating future profit growth from committed contracts.

Outlook

Management expects continued extended sales cycles due to customer caution over sovereignty, AI adoption, and cybersecurity. The demand for modernization remains strong, but decision-making is thoughtful and deliberate. For fiscal 2027, revenue is expected flat to down 2% constant currency, with stronger second-half performance. The evolving IBM relationship will persist as a headwind.

Growth Drivers

Key growth drivers include Kyndryl Consult (double-digit revenue growth for three consecutive years), hyperscaler-related revenue ($1.9 billion, up 59%), and new scope/new logos (over 30% of large deals). Private cloud and agentic AI modernization are emerging growth areas. The U.S. showed growth in Q4, while Europe faces delays due to sovereignty concerns.

Balance Sheet & CapEx

Net CapEx was $543 million in fiscal 2026, slightly above prior year. The company plans to invest in AI agents (Kyndryl Bridge), workforce rebalancing ($200 million charges in Q1 FY2027), and the acquisition of Solvinity for EUR 100 million. Annualized savings from workforce actions are expected at $400-$500 million in FY2028.

Margins

Adjusted EBITDA margin improved 100 basis points year-over-year, and adjusted pre-tax margin expanded 60 basis points. Signings have projected gross margins in the mid-20s and pre-tax margins in the high single digits. Advanced Delivery has generated $1 billion cumulative annualized savings. The workforce rebalancing is expected to be neutral to fiscal 2027 pre-tax income.

Key Risks

Risks include extended sales cycles and customer caution, the evolving IBM relationship causing revenue headwinds (>3 points), material weaknesses in internal controls (unresolved until FY2027), and cybersecurity and regulatory compliance costs. Workforce rebalancing execution is also a near-term risk.

Generated by AI · Q4 2026 results · Not investment advice

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.